Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
Mary Elizabeth Cox1, Jennifer Rowell1, Leonor Corsino1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition. Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durha...
Main Authors: | Mary Elizabeth Cox, Jennifer Rowell, Leonor Corsino, et al |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-01-01
|
Series: | Drug, Healthcare and Patient Safety |
Online Access: | http://www.dovepress.com/dipeptidyl-peptidase-4-inhibitors-in-the-management-of-type-2-diabetes-a3931 |
Similar Items
-
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
by: Chenkai Cui, et al.
Published: (2022-09-01) -
Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
by: Yun-Mi Jang, et al.
Published: (2011-04-01) -
Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
by: Lin YH, et al.
Published: (2019-12-01) -
Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
by: Shusuke Yagi, et al.
Published: (2015-08-01) -
Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014-12-01)